Company’s PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026 “We are very encouraged by the progress of our PALISADE-3 trial, which remains on track for a topline readout in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results